XENE on Nasdaq

Xenon Pharmaceuticals

We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need.5 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

1996Founded1

Compare with Adagene Inc., Bolt Biotherapeutics, Inc. or Ovid Therapeutics Inc., or pick any stock.

  • TickerXENE on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBurnaby1
  • Websitewww.xenon-pharma.com
  • Incorporated inBritish Columbia, Canada4
  • Business address200 - 3650 Gilmore Way, Burnaby4
  • Filer categoryLarge accelerated filer4
  • Legal formINCORPORATED / INCORPOREE3
  • LEI549300XV44Q9Z1MIPQ033
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressPO Box 10424, V7Y 1K2 Vancouver, Canada3
  • Registered withCorporations Canada, 37586563

See how the biggest companies compare on our leaderboards

We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-4974.3%Operating margin6
-4612.1%Net margin6
-59.5%Return on equity6
-$279.9MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$300.9M
  • Income tax0¢$1.0M

Out of $7.5M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$7.5M in 2025+10% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $6.8M$6.8M20192020: $32.2M$32.2M2020+371%2021: $18.4M$18.4M2021−43%2022: $9.4M$9.4M2022−49%2023: $0$020232024: $0$020242025: $7.5M$7.5M2025
Operating income789106-$373.1M in 2025+771% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$42.8M-$42.8M20192020: -$31.3M-$31.3M2020−27%2021: -$79.0M-$79.0M2021+152%2022: -$129.1M-$129.1M2022+63%2023: -$214.1M-$214.1M2023+66%2024: -$279.3M-$279.3M2024+30%2025: -$373.1M-$373.1M2025+34%
Net income789106-$345.9M in 2025+732% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$41.6M-$41.6M20192020: -$28.8M-$28.8M2020−31%2021: -$78.9M-$78.9M2021+174%2022: -$125.4M-$125.4M2022+59%2023: -$182.4M-$182.4M2023+45%2024: -$234.3M-$234.3M2024+28%2025: -$345.9M-$345.9M2025+48%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Collaboration revenue (note 10)$7.5M$0$0
Research and development$300.9M$210.4M$167.5M
General and administrative$79.6M$68.9M$46.5M
Total operating expenses$380.6M$279.3M$214.1M
Loss from operations-$373.1M-$279.3M-$214.1M
Interest income$26.8M$41.9M$27.6M
Unrealized fair value gain on trading securities$0$0$3.5M
Foreign exchange gain (loss)$1.3M-$1.1M$199.0K
Total other income$28.2M$40.9M$31.4M
Loss before income taxes-$344.9M-$238.4M-$182.7M
Income tax recovery (expense) (note 14)-$1.0M$4.1M$292.0K
Net loss-$345.9M-$234.3M-$182.4M
Unrealized gain (loss) on available-for-sale securities (note 5)$1.9M-$1.5M$2.9M
Comprehensive loss-$344.0M-$235.9M-$179.5M
Basic-$4.36-$3.01-$2.73
Diluted-$4.36-$3.01-$2.73
Basic79.3M shares77.9M shares66.9M shares
Diluted79.3M shares77.9M shares66.9M shares

Compare Xenon Pharmaceuticals with another company

Leadership

Who has led Xenon Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Simon N. Pimstone2014–2021
  2. Ian Mortimer2021–now

Chair

  1. Simon N. Pimstone2022

President

  1. Simon N. Pimstone2014–2017
  2. Ian Mortimer2018–now

Chief financial officer

  1. Ian Mortimer2014–2021
  2. Sherry Aulin2021–2024
  3. Thomas Patrick Kelly2025–now

Chief operating officer

  1. Ian Mortimer2015–2017
200020052010201520202025
Board members and other officers (24)

Timeline

  1. Jun 3, 2021New chief executive Ian Mortimer becomes CEO14
  2. Nov 4, 2014New chief executive Simon N. Pimstone becomes CEO15
  3. 1996Founded Founded1

Filings

303 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 55 major events, 122 insider forms, 30 large holders, 76 other. The latest 20:

  1. Oct 1, 20264 EDGAR
  2. Oct 1, 20264 EDGAR
  3. Sep 3, 20264 EDGAR
  4. Aug 31, 20264 EDGAR
  5. Aug 28, 2026144 EDGAR
  6. Aug 13, 20264 EDGAR
  7. Aug 13, 2026144 EDGAR
  8. Aug 13, 2026SCHEDULE 13G/A EDGAR
  9. Aug 7, 2026SCHEDULE 13G/A EDGAR
  10. Aug 6, 202610-Q EDGAR
  11. Aug 6, 20268-K EDGAR
  12. Aug 6, 2026SCHEDULE 13G/A EDGAR
  13. Jun 8, 20264 EDGAR
  14. Jun 8, 20264 EDGAR
  15. Jun 5, 2026144 EDGAR
  16. Jun 5, 2026144 EDGAR
  17. Jun 3, 20264 EDGAR
  18. Jun 3, 20264 EDGAR
  19. Jun 3, 20264 EDGAR
  20. Jun 3, 20264 EDGAR

The 303 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

53 open-market trades by officers, directors and large owners since October 2021: 2 buys and 51 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 28, 2026KENNEY CHRISTOPHER JOHNChief Medical OfficerSale7,068$60.25$425.8KForm 4
Aug 11, 2026GANNON STEVENDirectorSale10,000$64.06$640.6KForm 4
Jun 5, 2026PATOU GARYDirectorSale1,322$53.14$70.3KForm 4
Jun 5, 2026Cannon GillianDirectorSale1,190$53.14$63.2KForm 4
Mar 13, 2026KENNEY CHRISTOPHER JOHNChief Medical OfficerSale1,410$55.23$77.9KForm 4
Mar 13, 2026DiFabio AndreaChief Legal OfficerSale1,342$55.23$74.1KForm 4
Mar 13, 2026MORTIMER IANPRESIDENT & CEOSale7,308$55.23$403.6KForm 4
Mar 10, 2026KENNEY CHRISTOPHER JOHNChief Medical OfficerSale2,771$60.11$166.6KForm 4
Mar 10, 2026DiFabio AndreaChief Legal OfficerSale2,607$60.11$156.7KForm 4
Mar 10, 2026MORTIMER IANPRESIDENT & CEOSale11,269$60.11$677.4KForm 4
Mar 9, 2026MORTIMER IANPRESIDENT & CEOSale270,000$60.33$16.3MForm 4
Jan 2, 2026MORTIMER IANPRESIDENT & CEOSale40,000$44.43$1.8MForm 4
Dec 8, 2025MORTIMER IANPRESIDENT & CEOSale10,830$45.73$495.2KForm 4
Dec 5, 2025MORTIMER IANPRESIDENT & CEOSale14,375$45.03$647.3KForm 4
Nov 28, 2025MORTIMER IANPRESIDENT & CEOSale97$45.01$4.4KForm 4
Oct 1, 2025MORTIMER IANPRESIDENT & CEOSale25,000$40.16$1.0MForm 4
Jun 5, 2025GANNON STEVENDirectorSale3$30.48$91Form 4
Jan 27, 2025MORTIMER IANPRESIDENT & CEOSale16,315$40.50$660.8KForm 4
Jan 24, 2025MORTIMER IANPRESIDENT & CEOSale22,468$40.20$903.2KForm 4
Jan 23, 2025MORTIMER IANPRESIDENT & CEOSale16,217$40.08$650.0KForm 4

All 53 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC9,647,998$582.4M0.0%−1,170,493
BlackRock, Inc.7,522,482$454.1M0.0%+1,882,364
Avoro Capital Advisors LLC5,777,777$348.7M3.1%No change
Polar Capital Holdings Plc4,570,556$275.9M0.8%+165,244
Driehaus Capital Management LLC4,418,557$266.7M1.5%−73,096
Jupiter Topco LLC4,186,519$252.7M0.1%New
Jpmorgan Chase & Co2,617,360$157.4M0.0%+693,750
Capital International Investors2,361,639$142.5M0.0%−313,088
State Street Corp1,969,629$118.9M0.0%+249,096
Two Sigma Investments, LP1,642,848$99.2M0.1%+1,036,763
Deerfield Management Company, L.P.1,615,696$97.5M1.2%No change
Affinity Asset Advisors, LLC1,595,000$96.3M4.8%−80,000
Westfield Capital Management Co LP1,507,294$91.0M0.3%+105,811
Alliancebernstein L.P.1,562,276$90.8M0.0%+158,979
Franklin Resources Inc1,437,712$86.8M0.0%+157,135
Wellington Management Group Llp1,425,492$86.0M0.0%−3,404,149
Citadel Advisors LLC1,401,242$84.6M0.0%−1,251,748
Geode Capital Management, LLC1,370,114$82.7M0.0%+277,182
Siren, L.L.C.1,318,564$79.6M1.6%No change
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,290,731$77.9M0.1%−51,297
Pictet Asset Management Holding SA1,187,723$71.6M0.1%+508,014
Braidwell LP1,131,452$68.3M2.6%−207,000
Nuveen, LLC993,126$59.9M0.0%+743,090
Invesco Ltd.903,458$54.5M0.0%+844,355
Orbimed Advisors LLC892,471$53.9M1.0%−167,500

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52